KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Asset Writedowns and Impairment (2016 - 2020)

Resmed (RMD) has disclosed Asset Writedowns and Impairment for 9 consecutive years, with $9.1 million as the latest value for Q1 2020.

  • For the quarter ending Q1 2020, Asset Writedowns and Impairment rose 55.77% year-over-year to $9.1 million, compared with a TTM value of $20.7 million through Mar 2020, up 23.55%, and an annual FY2019 reading of $15.0 million, up 29.45% over the prior year.
  • Asset Writedowns and Impairment was $9.1 million for Q1 2020 at Resmed, up from $2.8 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $9.1 million in Q1 2020 and bottomed at $382000.0 in Q1 2017.
  • Average Asset Writedowns and Impairment over 4 years is $3.3 million, with a median of $1.7 million recorded in 2018.
  • The sharpest move saw Asset Writedowns and Impairment skyrocketed 483.25% in 2018, then fell 22.16% in 2019.
  • Year by year, Asset Writedowns and Impairment stood at $1.3 million in 2017, then decreased by 3.41% to $1.2 million in 2018, then soared by 126.68% to $2.8 million in 2019, then soared by 221.67% to $9.1 million in 2020.
  • Business Quant data shows Asset Writedowns and Impairment for RMD at $9.1 million in Q1 2020, $2.8 million in Q4 2019, and $2.6 million in Q3 2019.